LEADER 04080nam 22006375 450 001 9910298446903321 005 20251116151104.0 010 $a3-319-20273-1 024 7 $a10.1007/978-3-319-20273-0 035 $a(CKB)3710000000484441 035 $a(EBL)4178316 035 $a(SSID)ssj0001583756 035 $a(PQKBManifestationID)16263969 035 $a(PQKBTitleCode)TC0001583756 035 $a(PQKBWorkID)14866134 035 $a(PQKB)11726419 035 $a(DE-He213)978-3-319-20273-0 035 $a(MiAaPQ)EBC4178316 035 $a(PPN)190523832 035 $a(EXLCZ)993710000000484441 100 $a20150907d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe Adenosinergic System $eA Non-Dopaminergic Target in Parkinson?s Disease /$fedited by Micaela Morelli, Nicola Simola, Jadwiga Wardas 205 $a1st ed. 2015. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015. 215 $a1 online resource (344 p.) 225 1 $aCurrent Topics in Neurotoxicity,$x2363-9563 ;$v10 300 $aDescription based upon print version of record. 311 08$a3-319-20272-3 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aAdenosine A2A receptors: localization and function -- Allosteric Mechanisms in the adenosine A2A-dopamine D2 receptor heteromer -- Adenosine A2A receptor antagonists in drug development -- Adenosine A2A Receptors and Neurotrophic Factors: Relevance for Parkinson's Disease -- Role of adenosine A2A receptors in the control of neuroinflammation ? relevance for Parkinson?s disease -- Purines in Parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection -- Adenosine A2A receptor antagonists as drugs for symptomatic control of Parkinson?s disease in preclinical studies -- Dopamine/adenosine interactions related to tremor in animal models of Parkinsonism -- Adenosine A2A receptor antagonists in L-DOPA-induced motor fluctuations -- Adenosine A2A receptor-mediated control of non-motor functions in Parkinson?s disease -- Imaging Studies with A2A Receptor Antagonists -- Caffeine and neuroprotection in Parkinson's disease -- The story of istradefylline ? the first approved A2A antagonist for the treatment of Parkinson?s disease -- Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson's Disease -- Adenosinergic regulation of sleep-wake behavior in the basal ganglia. 330 $aAdenosine A2A receptor antagonists have shown great promise in the treatment of Parkinson's Disease and alleviation of symptoms. This book addresses various aspects of this class of drugs from their chemical development to their clinical use. Among the many insightful chapters contained in this book, there are three unique reviews that have not previously been published in any format: (1) a history of istradefylline, the first A2A antagonist approved for treatment of Parkinson's Disease, (2) an overview of neuroimaging studies in human health and disease, and (3) a study of urate as a possible biomarker and neuroprotectant. 410 0$aCurrent Topics in Neurotoxicity,$x2363-9563 ;$v10 606 $aNeurosciences 606 $aNeurology 606 $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006 606 $aNeurology$3https://scigraph.springernature.com/ontologies/product-market-codes/H36001 615 0$aNeurosciences. 615 0$aNeurology. 615 14$aNeurosciences. 615 24$aNeurology. 676 $a616.833 702 $aMorelli$b Micaela$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aSimola$b Nicola$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aWardas$b Jadwiga$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910298446903321 996 $aThe Adenosinergic System$92533196 997 $aUNINA